Skip to main content
Supplement ScienceSupplementScience

Huperzine A Dosage Guide

Evidence:Moderate
·

This content is for informational purposes only and does not constitute medical advice. Statements about dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary — consult your healthcare provider before starting any supplement. Full disclaimer

General Dosage

50-200mcg twice daily, with cycling recommended (5 days on, 2 days off)

Maximum dose: 400mcg/day (note: this is micrograms, not milligrams)

Dosage Recommendations

General recommendation: 50-200mcg twice daily, with cycling recommended (5 days on, 2 days off)

Timing: Twice daily (morning and early afternoon); cycle 5 days on, 2 off due to long half-life

Dosage by Condition

Memory enhancement
50-200mcg twice dailyModerate
Neuroprotection
200mcg twice dailyEmerging
Study/learning aid
50-100mcg twice dailyEmerging

Upper limit: 400mcg/day (note: this is micrograms, not milligrams)

Timing & Absorption

Twice daily (morning and early afternoon); cycle 5 days on, 2 off due to long half-life

Can be taken with or without food.

References

  1. RCTXu SS, Gao ZX, Weng Z, et al. (1999). Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease. Acta Pharmacologica Sinica. PubMed
  2. Meta-analysisYang G, Wang Y, Tian J, Liu JP (2013). Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials. PLoS ONE. DOI PubMed
  3. RCTSun QQ, Xu SS, Pan JL, et al. (1999). Huperzine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students. Acta Pharmacologica Sinica. PubMed
  4. Meta-analysisHuang P, Li B, Guo YH, Feng S, et al. (2019). [Efficacy and safety of huperzine A in treating patients with mild cognitive impairment: a systematic review and Meta-analysis].. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica. DOI PubMed
  5. Meta-analysisZheng W, Xiang YQ, Li XB, Ungvari GS, et al. (2016). Adjunctive huperzine A for cognitive deficits in schizophrenia: a systematic review and meta-analysis.. Human psychopharmacology. DOI PubMed
  6. Meta-analysisWang BS, Wang H, Wei ZH, Song YY, et al. (2009). Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis.. Journal of neural transmission (Vienna, Austria : 1996). DOI PubMed
  7. Li J, Wu HM, Zhou RL, Liu GJ, et al. (2008). Huperzine A for Alzheimer's disease.. The Cochrane database of systematic reviews. DOI PubMed
Show 3 more references
  1. Yue J, Dong BR, Lin X, Yang M, et al. (2012). Huperzine A for mild cognitive impairment.. The Cochrane database of systematic reviews. DOI PubMed
  2. Hao Z, Liu M, Liu Z, Lv D (2009). Huperzine A for vascular dementia.. The Cochrane database of systematic reviews. DOI PubMed
  3. Wessinger CM, Inman CL, Weinstock J, Weiss EP (2021). Effect of Huperzine A on Cognitive Function and Perception of Effort during Exercise: A Randomized Double-Blind Crossover Trial.. International journal of exercise science. DOI PubMed